Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?

What happened Despite a widespread rally across the biotech landscape last month the struggling clinical stage cancer company Celldex Therapeutics NASDAQ CLDX 160 still managed to shed 14 8 of its value in June 160 according to S amp P Global Market Intelligence